Latest On Alexion Pharmaceuticals, Inc (ALXN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-07-26 12:08 EST | News | EMA advisory committee backs Alexion’s Ultomiris for blood disorder in children | N/A |  |
| 2021-07-22 18:39 EST | News | ICER finds Alexion's Soliris lacks cost-effectiveness for myasthenia gravis | N/A | |
| 2021-07-20 18:40 EST | News | U.K. competition regulator to investigate AstraZeneca's $39B acquisition of Alexion | N/A | |
| 2021-07-20 18:35 EST | News | AstraZeneca files with European Commission for planned Alexion acquisition | N/A | |
| 2021-07-20 18:31 EST | News | AstraZeneca appoints Aradhana Sarin as new finance chief | N/A | |
About Alexion Pharmaceuticals, Inc (ALXN):
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase read more... III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
General
- Name Alexion Pharmaceuticals, Inc
- Symbol ALXN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 3,837
- Last Split Factor2:1
- Last Split Date2011-05-23
- Fiscal Year EndDecember
- IPO Date1996-02-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.alexion.com
Valuation
- Trailing PE 55.61
- Forward PE 12.02
- Price/Sales (Trailing 12 Mt.) 5.42
- Price/Book (Most Recent Quarter) 2.8
- Enterprise Value Revenue 5.33
- Enterprise Value EBITDA 32.28
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $13.08
- Next Year EPS Estimate $14.54
- Next Quarter EPS Estimate $3.10
- Profit Margin 10%
- Operating Margin 47%
- Return on Assets 10%
- Return on Equity 5%
- Revenue 6.07 billion
- Earnings Per Share $2.72
- Revenue Per Share $27.58
- Gross Profit 5.52 billion
- Quarterly Earnings Growth 15%
Highlights
- Market Capitalization 33.26 billion
- EBITDA 3.19 billion
- PEG Ratio 2.09
- Analyst Target Price $174.67
- Book Value Per Share $53.08
Share Statistics
- Shares Outstanding 219.85 million
- Shares Float 218.83 million
- % Held by Insiders 28%
- % Held by Institutions 93.36%
- Shares Short 8.45 million
- Shares Short Prior Month 7.9 million
- Short Ratio 3.29
- Short % of Float 4%
- Short % of Shares Outstanding 4%
Technicals
- Beta 1.24
- 52 Week High $162.6
- 52 Week Low $77.23
- 50 Day Moving Average 153.68
- 200 Day Moving Average 135.74
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
ESG Rating
Alexion Pharmaceuticals, Inc (ALXN) Dividend Calendar:
Alexion Pharmaceuticals, Inc (ALXN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Alexion Pharmaceuticals, Inc (ALXN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Alexion Pharmaceuticals, Inc (ALXN) Chart:
Alexion Pharmaceuticals, Inc (ALXN) News:
Below you will find a list of latest news for Alexion Pharmaceuticals, Inc (ALXN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Alexion Pharmaceuticals, Inc (ALXN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Alexion Pharmaceuticals, Inc (ALXN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-29 | 8-K (Current report) | |
| 2020-10-29 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-01 | 8-K (Current report) | |
| 2020-08-25 | 8-K (Current report) | |
| 2020-07-31 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-07-30 | 8-K (Current report) | |
| 2020-07-30 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-23 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-07-02 | 8-K (Current report) | |
| 2020-07-02 | SC TO-T/A (Tender offer statement by Third Party) | |
| 2020-07-02 | 8-K (Current report) | |
| 2020-06-25 | SC TO-T/A (Tender offer statement by Third Party) | |
| 2020-06-24 | SC TO-T/A (Tender offer statement by Third Party) | |
| 2020-06-15 | SC TO-T/A (Tender offer statement by Third Party) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | SC TO-T/A (Tender offer statement by Third Party) | |
Alexion Pharmaceuticals, Inc (ALXN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alexion Pharmaceuticals, Inc (ALXN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 28%
Institutional Ownership: 9336%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-06-08 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sell | 1,433.00 | 115.00 | 164,795.00 | 28,218.00 | |
| 2020-06-08 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sell | 5,420.00 | 114.61 | 621,186.20 | 29,651.00 | |
| 2020-05-14 | Francois Nader | Director | Buy | 3,468.00 | 10,345.00 | | ||
| 2020-05-14 | PAUL A FRIEDMAN | Director | Buy | 3,468.00 | 10,345.00 | | ||
| 2020-05-14 | Judith A Reinsdorf | Director | Buy | 3,468.00 | 10,920.00 | | ||
| 2020-05-14 | Deborah Dunsire | Director | Buy | 3,468.00 | 11,193.00 | | ||
| 2020-05-14 | Francois Nader | Director | Buy | 941.00 | 11,286.00 | | ||
| 2020-05-14 | Judith A Reinsdorf | Director | Buy | 595.00 | 11,515.00 | | ||
| 2020-05-14 | Deborah Dunsire | Director | Buy | 941.00 | 12,134.00 | | ||
| 2020-05-14 | John T Mollen | Director | Buy | 3,468.00 | 12,701.00 | | ||
| 2020-05-14 | David R Brennan | Director | Buy | 3,468.00 | 15,109.00 | | ||
| 2020-05-14 | David R Brennan | Director | Buy | 2,428.00 | 17,537.00 | | ||
| 2020-05-14 | Andreas Rummelt | Director | Buy | 3,468.00 | 25,614.00 | | ||
| 2020-05-14 | CHRISTOPHER J COUGHLIN | Director | Buy | 3,468.00 | 36,882.00 | | ||
| 2020-05-14 | CHRISTOPHER J COUGHLIN | Director | Buy | 2,774.00 | 39,656.00 | | ||
| 2020-05-14 | BROS. ADVISORS LP BAKER | Director | Buy | 3,468.00 | 7,845,024.00 | | ||
| 2020-05-14 | BROS. ADVISORS LP BAKER | Director | Buy | 1,189.00 | 7,846,213.00 | | ||
| 2020-05-14 | BROS. ADVISORS LP BAKER | Director | Buy | 3,468.00 | 997,764.00 | | ||
| 2020-05-14 | BROS. ADVISORS LP BAKER | Director | Buy | 1,189.00 | 998,953.00 | | ||
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 4,191.00 | 79.16 | 331,760.40 | 7,724,425.00 | |